hotspot -WSS

hotspot

author：leisure time 2025-09-14 18:30:46 - browse：1

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： 'Null' research findings aren't empty of meaning. Let's publish them

hotspot

focus

WSS

Group behind ProMed defends move to subscription

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Readout Newsletter: What happened with Sarepta's Duchenne data

Biden's order seeks to regulate AI risk without stifling innovation

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Wikipedia

hotspot

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Study links childhood stress with decline in older age

Affirmative action in medical school literally saved lives

Emergency medicine has repudiated 'excited delirium.' Now what?

Novavax promises a turnaround & Lilly roils the obesity market

Why Sanofi got shellacked over its spinoff

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: What happened with Sarepta's Duchenne data

What does generative AI mean for health care? We asked experts

Biden's order seeks to regulate AI risk without stifling innovation

entertainment

FDA scientists endorse Pfizer/BioNTech Covid

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Hospitals warn Medicare's drug payment fix is ‘unlawful’

CDC recommends rationing of RSV shot due to shortages

Group behind ProMed defends move to subscription

explore

hotspot

focus

explore